Damon Runyon Researchers

Meet Our Scientists
Keelan Z. Guiley, PhD

Dr. Guiley is focusing on the tumor suppressor protein p53, which is inactivated in half of all cancers, making it the most frequently mutated gene in cancer patients. Normally, when DNA is damaged, p53 stops cell division to allow the cell to repair acquired mutations. Without this safety measure, cells continue to divide and become cancerous. Dr. Guiley aims to develop a novel small molecule drug approach to target a common mutation in p53 and restore its function. These studies have the potential to benefit patients with many different types of cancer.

Project title: "Chemical probing of mutant p53"
Institution: University of California, San Francisco
Named Award: HHMI Fellow
Award Program: Fellow
Sponsor(s) / Mentor(s): Kevan M. Shokat, PhD
Cancer Type: All Cancers
Research Area: Chemical Biology